In this study, researchers aim to investigate whether canagliflozin, an anti-diabetic agent, can enhance the effectiveness of enzalutamide in preclinical models of prostate cancer (PrCa). Prostate cancer often becomes resistant to current therapies, such as enzalutamide, due to various molecular pathways. Canagliflozin has shown promise in suppressing these pathways in prostate cancer cells and tumors, […]
Read More